For thousands of years, Chinese doctors have been carrying forward the aspirations of the world and continuously achieving innovative breakthroughs in the clinical treatment pattern. Today's medical philosophy has gradually shifted the focus from "disease" itself to "health", from "how long can I live" to "how much I can live", paying more attention to the improvement of patients' quality of life, health maintenance, promotion and prolongation of life, and the improvement of human life quality.
However, the power of a person, a hospital, and a discipline is ultimately limited. Specialty subdivision, professional refinement, and medical knowledge specialization have a double-edged impact on the development of medicine. If you want to think about change, the collision of multiple disciplines and fields may be a light that illuminates the way forward. Interdisciplinary, cross-disciplinary linkages, as well as the development of telemedicine, can not only realize the whole process of disease management, but also act on the whole cycle of human life:
● Nurturing life - how to strengthen the health management of women's whole life cycle and help the long-term development of the population
● Improve life - how to scientifically link, from independent to comprehensive prevention and treatment, to achieve standardized management of common chronic diseases
●Prolonging life - how to multidisciplinary combination of attack to achieve the dual benefits of survival time and quality of life of tumor patients
Taking the most common disease of multidisciplinary integration - tumor - as an example, in the past, "talking about cancer discoloration", and now with the further maturity of traditional surgery, radiotherapy and chemotherapy technology, the rise of new targeted and immunotherapy methods, tumors have also entered the era of chronic disease management, and in the process of diagnosis and treatment of tumor patients, multidisciplinary collaboration and Internet medicine have played an increasingly significant role.
At the same time, in order to further achieve innovative breakthroughs in the clinical treatment pattern and achieve all-round benefits for Chinese patients in terms of drug efficacy, safety, economy and innovation, Chinese doctors are constantly exploring more suitable diagnosis and treatment methods based on Chinese evidence:
●From clinical practice to evidence-based evidence, how to find treatment methods for chronic diseases with Chinese characteristics
● How China Evidence Drives China Guidelines
How technological innovations, especially the development of reproductive medicine, support China's population strategy
●How patient-centered interdisciplinary disease management should be conducted
With these questions in mind, continuing the theme of "Passing on the Aspirations of the World and Creating a New Clinical Practice", the 4th Merck Medical Conference will be held online on March 19, 2022 from 08:30 - 15:40 Beijing time.
Wonderful sneak peek
The conference specially invited a number of experts and scholars with achievements in different disciplines to give special reports, aiming to promote and inherit the spirit of medicine, pursue medical science innovation, and promote interdisciplinary research and academic exchanges. The conference adopts the form of "global synchronous live broadcast" and "full AI translation" to connect online in real time, so that the wisdom light of medicine and the loud voice of science can go further and spread more widely, and draw a new chapter of "Healthy China"!
Meeting Schedule
March 19, 2022 08:30-15:40
The conference schedule and guest information are subject to the information on the day of the conference
Brilliant point of view
Professor Yu Qi, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Speech Topic: Nurturing Life - Women's Whole Life Cycle Health Management
Highlights sneak peek: women's health is the cornerstone of the healthy development of the next generation, the whole life cycle health management model, from the development of children and adolescents, infertility during childbearing age, to perimenopausal management, etc., women's health problems at all stages are worth paying attention to. Professor Yu Qi will focus on the key issues of women's health management in each cycle and explain how to meet the corresponding clinical challenges.
Prof. Jiayin Liu Jiangsu Provincial People's Hospital
Topic: Reproductive Medicine and Chinese Strategy
Highlights: The 7th National Population Census data released in 2021 shows that the mainland population is growing at a low rate and aging[1]. Coupled with the delay in childbearing age for women of childbearing age on the mainland, the incidence of infertility has increased. How can reproductive medicine meet the needs of the national population strategy and promote fertility? Based on China's national conditions and research results, Professor Liu Jiayin will show you the new direction of reproductive medicine under the national conditions of the mainland.
Professor Jin Lei Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Speech Topic: Multidisciplinary Contributes to The Long-term Development of The Population - Fertility Preservation
Highlights: For female patients, it is increasingly important to preserve reproductive ability so that they can have a complete family, and fertility preservation has become a multidisciplinary interdisciplinary field, requiring experts in multiple fields such as oncology, obstetrics and gynecology, reproductive endocrinology and other fields to jointly evaluate treatment plans, infertility risks and fertility preservation programs. What are the current advances in fertility preservation technology in women, and how is MDT clinical practice carried out? I believe that Professor Jin Lei's wonderful explanation will give you new insights on "MDT Helps Fertility Preservation".
Professor Wang Jiguang Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine
Speech Topic: Improving Life: Standardized Management of Hypertension in China
Highlights: In April 2018, the State Council officially issued the Opinions on Promoting the Development of "Internet + Medical Health", expressing a clear supportive attitude [2]. The epidemic in 2020 has once again promoted the rapid outbreak of the domestic Internet medical industry, and the intelligent diagnosis and treatment of chronic diseases has been put on the agenda. For the management of hypertension whose number of patients are at the forefront of chronic diseases, how to implement the concept of hypertension classification, staging and classification management in the clinic? With the intelligent Hypertension Excellence Center (iHEC), how to realize the standardization, informatization and intelligence of blood pressure management? Professor Wang Jiguang will explain the wisdom diagnosis and treatment of hypertension and standardized management in China.
Prof. Xiaoying Li Zhongshan Hospital Affiliated to Fudan University
Speech Topic: From the "DingHaishen Needle" of diabetes treatment, see how Chinese evidence is driving the development of the guidelines
Highlights sneak peek: Metformin as an "old drug", in previous research and clinical experience has confirmed its hypoglycemic effect, and in recent years, there have been new data in the fields of oncology, reproductive obstetrics and gynecology, neurology and other fields, and recently more Chinese scholars have published new findings on its targets in top journals. So, with the further development of China research, what new enlightenment has been brought? What is the guiding significance of China's clinical strategy for diabetes prevention and treatment? Based on Chinese evidence, Professor Li Xiaoying will explain the outstanding achievements of Chinese scholars in the field of diabetes prevention and treatment.
Professor Cai Sanjun Affiliated Cancer Hospital of Fudan University
Speech Topic: Prolonging Life: The Development of Colorectal Cancer MDT in China
Highlights: Colorectal cancer is the second most common cancer in China and the fourth in mortality, but the 5-year survival rate of stage I./II patients has reached 90%[3], which greatly improves the prognosis of patients. Tracing back to the roots, it is not difficult to find that the concept of multidisciplinary integrated treatment proposed in 2000 played a crucial role. From the era of single tumor treatment to the MDT era, what changes have taken place in the clinical diagnosis and treatment of colorectal cancer in China? How is MDT applied to colorectal cancer patients? I believe you can find the answer from Professor Cai's wonderful speech.
Professor Yuan Xianglin Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Speech Topic: From Practice to Evidence, The Path of Cancer Treatment with Chinese Characteristics
Highlights Sneak Peek: Research with Chinese Characteristics Promotes 2021 Edition of CSCO Bowel Cancer Guidelines Rewrite, How Did TJCC005 Research Do It? What are the key points to watch? The combination of clinical needs and basic research has driven the progress of tumor treatment, how to focus on the clinical pain points of radiation lung injury, break the situation from the genetic level, discover molecular markers and preventive drugs that predict radiation lung injury, and truly prevent problems before they occur? Professor Yuan Xianglin focused on the Chinese evidence and brought the latest demonstration on the path of cancer treatment with Chinese characteristics.
Prof. Peiguo Wang, Cancer Hospital, Tianjin Medical University
Speech Topic: Multidisciplinary Contribution to Survival Improvement - Integrated Prevention and Treatment of Head and Neck Squamous Cell Carcinoma
Highlights: MDT helps to shorten treatment wait times and improve treatment prognosis compared to the traditional single-discipline model, and approximately one-third of treatment patterns are likely to change, especially in patients with locally advanced head and neck squamous cell carcinoma, and the MDT principle should be throughout the treatment [4]. In this sharing, Professor Wang Peiguo will start from head and neck squamous cell carcinoma, and give excellent cases on how to implement MDT landing clinics, how to combine surgery, radiotherapy and chemotherapy technology and immunotherapy.
Prof. Xuan Jianwei, Institute of Pharmaceutical Economics, School of Pharmacy, Sun Yat-sen University
Topic: Development and Methodological Discussion of Health Technology Assessment
Highlights: With the development of the adjustment and standardization and institutionalization of the mainland medical insurance catalogue, health technology assessment has played an increasingly important role. What is the current status of health technology assessments in the UK, Germany and the US? What is the current situation on the mainland? What are the challenges? How to choose parameters that are more suitable for the Chinese scene in terms of the choice of reference drugs and the application of pharmacoeconomic models? Professor Xuan Jianwei will answer your questions one by one in his speech.
Professor Li Shunping, School of Public Health, Shandong University
Presentation Topic: Patient-reported outcome (PRO) research progress and application
Sneak peek: Patients' thoughts are especially important in the safety reporting process for drug clinical development, and these voices and opinions not only increase the amount of information on pharmacovigilance, but also improve the quality of reporting [5]. What requirements does the Guidelines for the Application of Patient Reported Outcomes in Drug Clinical Development (Trial) issued by Mainland China in January 2022, such as integration with clinical practice? I believe that Professor Li Shunping's explanation will give you a new understanding of the patient reporting outcome (PRO).
Let's gather at the 4th Merck Medical Congress to start a new journey of medicine
Approval number CN-NONCMCGM-00022, valid until March 14, 2023
Content Planner: Yang Chengyun
Project review: Zhao Xiyue
Title image source: Stand Cool Helo
Resources:
[1]. Main data of the Seventh National Population Census (Communiqué No. 1-8)
[2]. Revision Committee of China Guidelines for the Prevention and Treatment of Hypertension. 2018 Revised Guidelines for the Prevention and Treatment of Hypertension in China[J]. Cardiovascular and Cerebrovascular Disease Prevention and Treatment, 2019, 019(001):1-44.
[3]. Early diagnosis and early treatment group of oncology branch of Chinese Medical Association. Expert consensus on early diagnosis and early treatment of colorectal cancer in China[J] . Chinese Medical Journal,2020,100 (22): 1691-1698.
Chinese Society of Clinical Oncology. Head and Neck Tumor Diagnosis and Treatment Guidelines (2020 Edition)
Drug Evaluation Center of State Drug Administration. Guidelines for the application of patient-reported outcomes in clinical studies of the drug